NeoChord commences patient enrollment in its TACT European clinical trial

NeoChord, Inc.Oct 28 2009

NeoChord, Inc., a venture-backed, Minneapolis-based medical technology company, announced today that it has enrolled the first patient in its European clinical trial. The trial, known as TACT (transapical artificial chordae tendineae) is being conducted in Germany, Denmark, Czech Republic and Norway.

“We are very pleased with the early results of this first procedure,” said Per Wierup and Sten Lyager Nielsen, the cardiac surgeons who performed the surgery. “The patient is an otherwise healthy, very active 47-year-old male who preferred to not have a sternotomy or cardiopulmonary bypass to fix his severe mitral regurgitation. The NeoChord approach has successfully treated his mitral regurgitation and potentially offers him a quick return to his military career and favorite hobby, scuba diving.”

Intra-operative transesophageal echocardiography (TEE) confirmed that the patient’s severe, eccentric mitral regurgitation was reduced to zero or trace mitral regurgitation. Giovanni Speziali, MD, the cardiac surgeon who is the primary inventor of the NeoChord device also attended the procedure. “These results, although early, are equivalent to what we obtain in traditional open heart surgery for correction of mitral regurgitation,” said Dr. Speziali.

The NeoChord procedure was developed to treat sub-valvular chordal damage – the primary cause of degenerative mitral regurgitation – via minimally invasive implantation of artificial chordae tendineae. The technology was developed by Speziali and other doctors at the Mayo Clinic and exclusively licensed to NeoChord.

“We’re very pleased to have achieved the first-in-man milestone and want to extend our very best wishes to the patient and his family,” said John Seaberg, CEO of NeoChord. “This successful outcome is the result of several years of hard work by our product development staff and our clinical advisors. I’m extremely proud of the extended NeoChord team.”